Jump to content

Stergios Boussios

Add links
From Wikipedia, the free encyclopedia

Stergios Boussios is a Greek oncologist and researcher [1] known for his contributions to medical oncology,[2][3] particularly in cancer management during pregnancy [4] and the study of circulating tumor cells in cancer of unknown primary (CUP).

Research contributions

[edit]

Boussios is actively involved in clinical trials and translational research.[5][6]

Boussios is the Principal Investigator for several international clinical trials, including LITESPARK-005,[7] STAMPEDE,[8][9] and STAR.[10]

Additionally, he has worked with Professor S.V. Ovsepian, Faculty of Engineering and Science, University of Greenwich London, UK on an orthogonal approach for analyzing underivatized steroid hormones using ultrahigh-performance supercritical fluid chromatography-mass spectrometry.[11]

References

[edit]
  1. ^ "Stergios Boussios". scholar.google.com. Retrieved 2025-02-14.
  2. ^ "Research helps advance treatment for kidney cancer". Medway NHS. Retrieved 2025-02-03.
  3. ^ "Stergios Boussios | University of Ioannina, Greece". www.esmo.org. Retrieved 2025-02-03.
  4. ^ Dai, Kunhan; Jiang, Wencheng; Chen, Siyu; Luo, Shengjun; Ding, Siwei; Wang, Delin (2022-10-18). "Case report: Going through pregnancy safely after twice partial nephrectomy for bilateral kidneys with HLRCC-associated RCC". Frontiers in Oncology. 12. doi:10.3389/fonc.2022.932996. ISSN 2234-943X. PMC 9623055. PMID 36330476.
  5. ^ Boussios, Stergios; Moschetta, Michele; McLachlan, Jennifer; Banerjee, Susana (2015). "Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor". Case Reports in Oncological Medicine. 2015 (1): 574708. doi:10.1155/2015/574708. ISSN 2090-6714. PMC 4698943. PMID 26798532.
  6. ^ Zhang, Yunting; Yang, Fanchun; Wang, Jining; Fu, Hui; Shen, Fuming; Liu, Jie; Li, Dongjie (2024-06-05). "Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review". Frontiers in Immunology. 15. doi:10.3389/fimmu.2024.1382964. ISSN 1664-3224. PMC 11188369. PMID 38903494.
  7. ^ Choueiri, Toni K.; Powles, Thomas; Peltola, Katriina; de Velasco, Guillermo; Burotto, Mauricio; Suarez, Cristina; Ghatalia, Pooja; Iacovelli, Roberto; Lam, Elaine T.; Verzoni, Elena; Gümüş, Mahmut; Stadler, Walter M.; Kollmannsberger, Christian; Melichar, Bohuslav; Venugopal, Balaji (2024-08-22). "Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma". The New England Journal of Medicine. 391 (8): 710–721. doi:10.1056/NEJMoa2313906. ISSN 1533-4406. PMID 39167807.
  8. ^ Attard, Gerhardt; Murphy, Laura; Clarke, Noel W.; Sachdeva, Ashwin; Jones, Craig; Hoyle, Alex; Cross, William; Jones, Robert J.; Parker, Christopher C.; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Gilson, Clare; Rush, Hannah; Abdel-Aty, Hoda (May 2023). "Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol". The Lancet. Oncology. 24 (5): 443–456. doi:10.1016/S1470-2045(23)00148-1. ISSN 1474-5488. PMC 7616864. PMID 37142371.
  9. ^ Attard, Gerhardt; Murphy, Laura; Clarke, Noel W.; Cross, William; Jones, Robert J.; Parker, Christopher C.; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L.; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar (2022-01-29). "Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol". Lancet. 399 (10323): 447–460. doi:10.1016/S0140-6736(21)02437-5. ISSN 1474-547X. PMC 8811484. PMID 34953525.
  10. ^ Brown, Janet E.; Royle, Kara-Louise; Gregory, Walter; Ralph, Christy; Maraveyas, Anthony; Din, Omar; Eisen, Timothy; Nathan, Paul; Powles, Tom; Griffiths, Richard; Jones, Robert; Vasudev, Naveen; Wheater, Matthew; Hamid, Abdel; Waddell, Tom (March 2023). "Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial". The Lancet. Oncology. 24 (3): 213–227. doi:10.1016/S1470-2045(22)00793-8. ISSN 1474-5488. PMID 36796394.
  11. ^ Devo, Perry; Cretu, Victoria; Radhakrishnan, Harsha; Hamilton-Pink, Darren; Boussios, Stergios; Ovsepian, Saak V. (2024-11-15). "An orthogonal approach for analysis of underivatized steroid hormones using ultrahigh performance supercritical fluid chromatography-mass spectrometry (UHPSFC-MS)". Journal of Neural Transmission (Vienna, Austria: 1996). doi:10.1007/s00702-024-02862-3. ISSN 1435-1463. PMID 39545973.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Stergios_Boussios&oldid=1278394410"